{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:59:25Z","timestamp":1790625565328,"version":"4.1.0"},"reference-count":118,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":251,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) requires causal attribution rather than reliance on a single triglyceride (TG) threshold. Early TG measurement and assessment of competing or coexisting causes are essential because fasting, fluids, and correction of metabolic stress can produce substantial early TG decline. Severity should be determined by serial organ-function assessment using revised Atlanta and Modified Marshall criteria rather than TG concentration alone. Acute management should prioritize standard pancreatitis care, moderate crystalloid resuscitation, analgesia, early oral or enteral nutrition, and correction of genuine metabolic drivers. Intravenous insulin is appropriate for diabetic ketoacidosis, uncontrolled diabetes, marked hyperglycemia, or clinically important insulin deficiency, but current evidence does not support routine insulin solely for TG lowering in insulin-sufficient patients. Heparin should not be used for TG lowering. Therapeutic plasma exchange (TPE) produces rapid biochemical TG clearance, but randomized and adjusted observational evidence has not established improvement in organ failure, pancreatic necrosis, hospital stay, or mortality. TPE should therefore not be used as routine or rescue TG-lowering therapy; exceptional multidisciplinary deliberation may occur only in narrowly defined circumstances and should not be interpreted as an evidence-based indication or recommendation. After recovery, phenotype-directed assessment using fasting lipids, apolipoprotein B, evaluation of secondary drivers, and selective genetic testing can distinguish familial from multifactorial chylomicronemia and guide prevention. Hepatic apolipoprotein C-III (apoC-III) inhibition currently has the strongest randomized evidence for reducing pancreatitis events in relevant chylomicronemia populations. Management should prioritize prevention of organ injury during the acute episode and prevention of subsequent pancreatitis rather than the fastest possible TG decline.<\/jats:p>","DOI":"10.1093\/gastro\/goag107","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:46:54Z","timestamp":1789040814000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond triglyceride clearance: rethinking hypertriglyceridemia-associated acute pancreatitis in the apoC-III era"],"prefix":"10.1093","volume":"14","author":[{"given":"Serge","family":"Chooklin","sequence":"first","affiliation":[{"name":"Surgical Center, Saint Paraskeva Medical Center , Lviv 79000,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhii","family":"Chuklin","sequence":"additional","affiliation":[{"name":"Surgical Center, Saint Paraskeva Medical Center , Lviv 79000,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092815145986700_goag107-B1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pan.2020.03.018","article-title":"Hypertriglyceridemia-induced acute pancreatitis: a prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases","volume":"20","author":"Mosztbacher","year":"2020","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pan.2020.02.010","article-title":"Clinical features of hypertriglyceridemia-induced acute pancreatitis in an international, multicenter, prospective cohort (APPRENTICE consortium)","volume":"20","author":"Pothoulakis","year":"2020","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health Dis"},{"key":"2026092815145986700_goag107-B4","first-page":"922","article-title":"Hypertriglyceridemia and its relationship with all-cause mortality and pancreatitis: results from a large retrospective clinical registry","volume":"19","author":"Vlacho","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2022.11.006","article-title":"Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: a prospective cohort study","volume":"17","author":"Ding","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.pan.2025.04.020","article-title":"International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: supported and endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society","volume":"25","author":"IAP\/APA\/EPC\/IPC\/JPS Working Group","year":"2025","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13017-019-0247-0","article-title":"2019 WSES guidelines for the management of severe acute pancreatitis","volume":"14","author":"Lepp\u00e4niemi","year":"2019","journal-title":"World J Emerg Surg"},{"key":"2026092815145986700_goag107-B8","doi-asserted-by":"crossref","first-page":"e184785","DOI":"10.1172\/JCI184785","article-title":"Prospective observational study and mechanistic evidence showing lipolysis of circulating triglycerides worsens hypertriglyceridemic acute pancreatitis","volume":"135","author":"Rajalingamgari","year":"2024","journal-title":"J Clin Invest"},{"key":"2026092815145986700_goag107-B9","doi-asserted-by":"crossref","first-page":"870067","DOI":"10.3389\/fmed.2022.870067","article-title":"Comparable triglyceride reduction with plasma exchange and insulin in acute pancreatitis \u2013 a randomized trial","volume":"9","author":"Gubensek","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026092815145986700_goag107-B10","doi-asserted-by":"crossref","first-page":"e2320802","DOI":"10.1001\/jamanetworkopen.2023.20802","article-title":"Early plasmapheresis among patients with hypertriglyceridemia-associated acute pancreatitis","volume":"6","author":"Cao","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026092815145986700_goag107-B11","doi-asserted-by":"crossref","first-page":"e2542124","DOI":"10.1001\/jamanetworkopen.2025.42124","article-title":"Low-molecular-weight heparin plus insulin in hypertriglyceridemic acute pancreatitis: a randomized clinical trial","volume":"8","author":"He","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092815145986700_goag107-B12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","volume":"110","author":"Spagnuolo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092815145986700_goag107-B13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20142012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"2026092815145986700_goag107-B18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/joim.12925","article-title":"Conservative management in hypertriglyceridemia-associated pancreatitis","volume":"286","author":"Berberich","year":"2019","journal-title":"J Intern Med"},{"key":"2026092815145986700_goag107-B19","doi-asserted-by":"crossref","first-page":"bvz019","DOI":"10.1210\/jendso\/bvz019","article-title":"Intravenous insulin versus conservative management in hypertriglyceridemia-associated acute pancreatitis","volume":"4","author":"Dhindsa","year":"2020","journal-title":"J Endocr Soc"},{"key":"2026092815145986700_goag107-B20","doi-asserted-by":"crossref","first-page":"e001620","DOI":"10.1136\/bmjgast-2024-001620","article-title":"Triglyceride lowering in patients with different severities of hypertriglyceridaemia-associated acute pancreatitis: secondary analysis of a multicentre, prospective cohort study","volume":"12","author":"Luo","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"2026092815145986700_goag107-B21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-022-01525-5","article-title":"Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study","volume":"21","author":"Patel","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026092815145986700_goag107-B22","doi-asserted-by":"crossref","first-page":"G279","DOI":"10.1152\/ajpgi.00074.2023","article-title":"Relationship of circulating levels of long-chain fatty acids to persistent organ failure in acute pancreatitis","volume":"325","author":"Phillips","year":"2023","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026092815145986700_goag107-B23","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.14309\/ajg.0000000000003319","article-title":"Clinical outcomes in a multicenter cohort involving 919 patients with hypertriglyceridemia-associated acute pancreatitis","volume":"120","author":"Deng","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026092815145986700_goag107-B24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O\u2019Dea","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026092815145986700_goag107-B25","doi-asserted-by":"crossref","first-page":"117489","DOI":"10.1016\/j.atherosclerosis.2024.117489","article-title":"Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia","volume":"392","author":"Guay","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026092815145986700_goag107-B26","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.3390\/ijms27125443","article-title":"Genetic determinants of severe hypertriglyceridemia: rare variants in LPL, APOC2, APOA5, GPIHBP1, LMF1, APOE and polygenic risk","volume":"27","author":"Blokhina","year":"2026","journal-title":"Int J Mol Sci"},{"key":"2026092815145986700_goag107-B27","doi-asserted-by":"crossref","first-page":"107ra110","DOI":"10.1126\/scitranslmed.3002573","article-title":"Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity","volume":"3","author":"Navina","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026092815145986700_goag107-B28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1172\/JCI132767","article-title":"Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation","volume":"130","author":"de Oliveira","year":"2020","journal-title":"J Clin Invest"},{"key":"2026092815145986700_goag107-B29","doi-asserted-by":"crossref","first-page":"29661","DOI":"10.1038\/s41598-025-15391-0","article-title":"Fatty acid analysis identifies an aberrant circulating triglyceride composition in patients with hypertriglyceridemia-induced acute pancreatitis","volume":"15","author":"Leikin-Frenkel","year":"2025","journal-title":"Sci Rep"},{"key":"2026092815145986700_goag107-B30","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41598-025-85847-w","article-title":"Ultra-early indicators of acute hypertriglyceridemic pancreatitis may influence treatment decision-making","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"key":"2026092815145986700_goag107-B31","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.3748\/wjg.v21.i32.9534","article-title":"Distinctive roles of unsaturated and saturated fatty acids in hyperlipidemic pancreatitis","volume":"21","author":"Chang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026092815145986700_goag107-B32","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1007\/s10753-025-02254-z","article-title":"Baicalein reduces pyroptosis of acinar cells in hyperlipidemic acute pancreatitis by inhibiting M1 polarization of macrophages via the HMGB1\/TLR4\/NLRP3 pathway","volume":"48","author":"Wang","year":"2025","journal-title":"Inflammation"},{"key":"2026092815145986700_goag107-B33","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1038\/s41598-024-60159-7","article-title":"Liproxstatin-1 attenuates acute hypertriglyceridemic pancreatitis through inhibiting ferroptosis in rats","volume":"14","author":"Xiang","year":"2024","journal-title":"Sci Rep"},{"key":"2026092815145986700_goag107-B34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.24976\/Discov.Med.202537197.98","article-title":"Inhibiting NLRP3\/Caspase-1\/GSDMD-mediated pyroptosis: a new role of GADD45B\u2019s role in hypertriglyceridemia-induced acute pancreatitis","volume":"37","author":"Zhou","year":"2025","journal-title":"Discov Med"},{"key":"2026092815145986700_goag107-B35","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.2147\/IJGM.S542782","article-title":"MCU-Mediated SIRT3 inhibition drives oxidative stress-induced cytoskeletal disruption in pancreatic ductal epithelium: a mechanism of hypertriglyceridemic acute pancreatitis","volume":"18","author":"Hong","year":"2025","journal-title":"Int J Gen Med"},{"key":"2026092815145986700_goag107-B36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/diagnostics14111105","article-title":"Hypertriglyceridemia-induced acute pancreatitis-the milky way constellation-the seven-year experience of a large tertiary centre","volume":"14","author":"Edu","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026092815145986700_goag107-B37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000512682","article-title":"Association of serum triglyceride levels with severity in acute pancreatitis: results from an international, multicenter cohort study","volume":"102","author":"Pothoulakis","year":"2021","journal-title":"Digestion"},{"key":"2026092815145986700_goag107-B38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.pan.2025.09.032","article-title":"Prognostic impact of serum triglycerides in acute pancreatitis: evidence from multi-center cohort study using a common data model","volume":"25","author":"Park","year":"2025","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2024.03.022","article-title":"Recurrence of hypertriglyceridemia-associated acute pancreatitis: a multicenter, prospective cohort study","volume":"125","author":"Ding","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026092815145986700_goag107-B40","doi-asserted-by":"crossref","first-page":"1079637","DOI":"10.3389\/fmed.2023.1079637","article-title":"Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis","volume":"10","author":"Guan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026092815145986700_goag107-B41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12944-023-01840-0","article-title":"Number of recurrences is significantly associated with the post-acute pancreatitis diabetes mellitus in a population with hypertriglyceridemic acute pancreatitis","volume":"22","author":"Tu","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026092815145986700_goag107-B42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12876-025-03760-y","article-title":"Readmission of patients with hypertriglyceridemia-induced acute pancreatitis: a prospective cohort study","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026092815145986700_goag107-B43","doi-asserted-by":"crossref","first-page":"1741265","DOI":"10.3389\/fnut.2026.1741265","article-title":"Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study","volume":"13","author":"Liu","year":"2026","journal-title":"Front Nutr"},{"key":"2026092815145986700_goag107-B44","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacl.2025.08.017","article-title":"Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis","volume":"19","author":"Broder","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B45","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092815145986700_goag107-B46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis"},{"key":"2026092815145986700_goag107-B47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ueg2.12057","article-title":"Mortality in acute pancreatitis with persistent organ failure is determined by the number, type, and sequence of organ systems affected","volume":"9","author":"Machicado","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026092815145986700_goag107-B48","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1136\/gut.2008.152702","article-title":"The early prediction of mortality in acute pancreatitis: a large population-based study","volume":"57","author":"Wu","year":"2008","journal-title":"Gut"},{"key":"2026092815145986700_goag107-B49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/ajg.2009.28","article-title":"A prospective evaluation of the bedside index for severity in acute pancreatitis score in assessing mortality and intermediate markers of severity in acute pancreatitis","volume":"104","author":"Singh","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2026092815145986700_goag107-B50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s10620-019-05827-9","article-title":"Comparison of scoring systems in predicting severity and prognosis of hypertriglyceridemia-induced acute pancreatitis","volume":"65","author":"Li","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2026092815145986700_goag107-B51","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-026-02682-y","article-title":"Are BISAP and APACHE II scores still useful to identify high-risk patients in acute pancreatitis? A retrospective multicenter analysis on 450 patients","author":"Chiarello","year":"2026","journal-title":"Updates Surg"},{"key":"2026092815145986700_goag107-B52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.gastro.2009.03.056","article-title":"Early changes in blood urea nitrogen predict mortality in acute pancreatitis","volume":"137","author":"Wu","year":"2009","journal-title":"Gastroenterology"},{"key":"2026092815145986700_goag107-B53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/bjs.5290","article-title":"Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis","volume":"93","author":"Mofidi","year":"2006","journal-title":"Br J Surg"},{"key":"2026092815145986700_goag107-B54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2004.039883","article-title":"Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis","volume":"53","author":"Johnson","year":"2004","journal-title":"Gut"},{"key":"2026092815145986700_goag107-B55","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/SLA.0b013e318256f778","article-title":"Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation","volume":"256","author":"Dellinger","year":"2012","journal-title":"Ann Surg"},{"key":"2026092815145986700_goag107-B56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/SLA.0000000000000264","article-title":"The role of organ failure and infection in necrotizing pancreatitis: a prospective study","volume":"259","author":"Guo","year":"2014","journal-title":"Ann Surg"},{"key":"2026092815145986700_goag107-B57","doi-asserted-by":"crossref","first-page":"613698","DOI":"10.2147\/JIR.S613698","article-title":"Development and validation of an early severity prediction model for hypertriglyceridemia-associated acute pancreatitis: a multicenter cohort study","volume":"19","author":"Yao","year":"2026","journal-title":"J Inflamm Res"},{"key":"2026092815145986700_goag107-B58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2202884","article-title":"Aggressive or moderate fluid resuscitation in acute pancreatitis","volume":"387","author":"de-Madaria","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/SLA.0000000000004596","article-title":"Immediate oral refeeding in patients with mild and moderate acute pancreatitis: a multicenter, randomized controlled trial (PADI trial)","volume":"274","author":"Ram\u00edrez-Maldonado","year":"2021","journal-title":"Ann Surg"},{"key":"2026092815145986700_goag107-B60","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1404393","article-title":"Early versus on-demand nasoenteric tube feeding in acute pancreatitis","volume":"371","author":"Bakker","year":"2014","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2003.12.050","article-title":"Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial","volume":"126","author":"Isenmann","year":"2004","journal-title":"Gastroenterology"},{"key":"2026092815145986700_goag107-B62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/01.sla.0000250414.09255.84","article-title":"Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study","volume":"245","author":"Dellinger","year":"2007","journal-title":"Ann Surg"},{"key":"2026092815145986700_goag107-B63","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/10600280231155921","article-title":"Acute management of hypertriglyceridemia with a disease-specific intravenous insulin infusion order set","volume":"57","author":"Ibarra","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2026092815145986700_goag107-B64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/87551225231151570","article-title":"Effectiveness of an intravenous insulin-based treatment protocol for the management of hypertriglyceridemia-associated acute pancreatitis","volume":"39","author":"Perez","year":"2023","journal-title":"J Pharm Technol"},{"key":"2026092815145986700_goag107-B65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MEG.0000000000002025","article-title":"Continuous insulin therapy versus apheresis in patients with hypertriglyceridemia-associated pancreatitis","volume":"34","author":"Araz","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026092815145986700_goag107-B66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cen.70071","article-title":"Evaluation of a fixed-dose insulin protocol for hypertriglyceridemia-induced acute pancreatitis: a retrospective cohort study","volume":"104","author":"Yacine","year":"2026","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026092815145986700_goag107-B67","doi-asserted-by":"crossref","first-page":"e42674","DOI":"10.1097\/MD.0000000000042674","article-title":"Effectiveness of continuous intravenous insulin infusion in hypertriglyceridemia-induced acute pancreatitis of varying severity: a longitudinal study","volume":"104","author":"Le","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026092815145986700_goag107-B68","doi-asserted-by":"crossref","first-page":"dgaa674","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092815145986700_goag107-B69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-2275(20)41211-8","article-title":"Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation","volume":"35","author":"Weintraub","year":"1994","journal-title":"J Lipid Res"},{"key":"2026092815145986700_goag107-B70","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/00365521.2024.2342406","article-title":"The effect of serum triglyceride levels and different lipid-lowering methods on the prognosis of hypertriglyceridemic acute pancreatitis: a single-center 12-year retrospective study by propensity score matching","volume":"59","author":"Liu","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"2026092815145986700_goag107-B71","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.pan.2026.07.006","article-title":"Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial","volume":"26","author":"Ding","year":"2026","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B72","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/ueg2.70097","article-title":"Plasmapheresis in acute hypertriglyceridemia-induced pancreatitis-the PHIP-JuGa-study","volume":"13","author":"Staudacher","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026092815145986700_goag107-B73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13613-024-01285-3","article-title":"Impact of therapeutic plasmapheresis on the duration of organ failure in patients with hypertriglyceridemia-associated acute pancreatitis","volume":"14","author":"Wang","year":"2024","journal-title":"Ann Intensive Care"},{"key":"2026092815145986700_goag107-B74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12902-024-01562-z","article-title":"Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year\u2019s experience","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2026092815145986700_goag107-B75","doi-asserted-by":"crossref","first-page":"e70053","DOI":"10.1002\/jca.70053","article-title":"The role of therapeutic plasma exchange in treating hypertriglyceridemia-associated acute pancreatitis: a real-world effectiveness analysis using the TriNetX global collaborative network","volume":"40","author":"Amin","year":"2025","journal-title":"J Clin Apher"},{"key":"2026092815145986700_goag107-B76","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2026.03.008","article-title":"Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: a 10-year triglyceride-stratified retrospective study","volume":"20","author":"Qi","year":"2026","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B77","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/1744-9987.14173","article-title":"Complications of therapeutic plasma exchange: a retrospective, single-center study of 2505 procedures performed in 338 patients over 15\u2009years","volume":"28","author":"Vural","year":"2024","journal-title":"Ther Apher Dial"},{"key":"2026092815145986700_goag107-B78","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1111\/trf.15532","article-title":"Efficacy of therapeutic plasma exchange in reducing the incidence of recurrent pancreatitis related to familial chylomicronemia","volume":"59","author":"Fitts","year":"2019","journal-title":"Transfusion"},{"key":"2026092815145986700_goag107-B79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1753495X241283628","article-title":"Familial chylomicronaemia syndrome in pregnancy \u2013 report of two cases managed with plasma exchange","volume":"18","author":"Dos Santos","year":"2025","journal-title":"Obstet Med"},{"key":"2026092815145986700_goag107-B80","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/trf.16214","article-title":"Retrospective analysis of outcomes in patients with acute hypertriglyceridemic pancreatitis treated without therapeutic plasma exchange","volume":"61","author":"Hutchison","year":"2021","journal-title":"Transfusion"},{"key":"2026092815145986700_goag107-B81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pan.2025.01.008","article-title":"Effect of plasmapheresis versus standard medical treatment in patients with hypertriglyceridemia-associated acute pancreatitis complicated by early organ failure (PERFORM-R): study design and rationale of a multicenter, pragmatic, registry-based randomized controlled trial","volume":"25","author":"Zhou","year":"2025","journal-title":"Pancreatology"},{"key":"2026092815145986700_goag107-B82","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/ATVBAHA.124.320955","article-title":"Ethnic diversity and distinctive features of familial versus multifactorial chylomicronemia syndrome: insights from the UK FCS national registry","volume":"44","author":"Bashir","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026092815145986700_goag107-B83","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/ATVBAHA.125.323340","article-title":"Contemporary management of familial and multifactorial chylomicronemia syndromes in italy: insights from the national LIPIGEN registry","volume":"45","author":"D\u2019Erasmo","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026092815145986700_goag107-B84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026092815145986700_goag107-B85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B86","doi-asserted-by":"crossref","first-page":"117476","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026092815145986700_goag107-B87","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacl.2025.07.008","article-title":"Brief communication: strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study","volume":"19","author":"Brown","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jacl.2025.11.005","article-title":"Application of the North American Familial Chylomicronemia Syndrome Score (NAFCS Score) in monogenic hypertriglyceridemia patients: a single-center Turkish cohort study","volume":"20","author":"S\u0131ms\u0131r","year":"2026","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B89","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jacl.2026.03.004","article-title":"Comparison of different \u201cfamilial chylomicronemia syndrome\u201d clinical diagnosis scoring systems in patients with persistent chylomicronemia","volume":"20","author":"Brisson","year":"2026","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B90","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B91","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1194\/jlr.R120001116","article-title":"Chylomicronemia from GPIHBP1 autoantibodies","volume":"61","author":"Miyashita","year":"2020","journal-title":"J Lipid Res"},{"key":"2026092815145986700_goag107-B92","first-page":"1085","article-title":"Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia","volume":"19","author":"Hang","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12944-022-01768-x","article-title":"Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010\u20132020: a cross-sectional study","volume":"22","author":"Rodriguez","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026092815145986700_goag107-B94","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"2026092815145986700_goag107-B95","doi-asserted-by":"crossref","first-page":"bvaf025","DOI":"10.1210\/jendso\/bvaf025","article-title":"Treatment with evinacumab links a new pathogenic variant in the LPL gene to persistent chylomicronemia","volume":"9","author":"Larouche","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026092815145986700_goag107-B96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3476(98)70280-X","article-title":"Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study","volume":"133","author":"Feoli-Fonseca","year":"1998","journal-title":"J Pediatr"},{"key":"2026092815145986700_goag107-B97","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B99","doi-asserted-by":"crossref","first-page":"178148","DOI":"10.1016\/j.ejphar.2025.178148","article-title":"Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis","volume":"1006","author":"Chen","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"2026092815145986700_goag107-B100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092815145986700_goag107-B101","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026092815145986700_goag107-B102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026092815145986700_goag107-B103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B104","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.70623","article-title":"Clinical trial: plozasiran prevents recurrent pancreatitis in adults with very severe hypertriglyceridemia-results of a post hoc analysis of the phase 3 PALISADE study","volume":"63","author":"Loomba","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092815145986700_goag107-B105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026092815145986700_goag107-B106","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2025.07.005","article-title":"Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: a phase 2b trial","volume":"19","author":"Rosenson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B107","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"2026092815145986700_goag107-B108","volume-title":"Tryngolza (Olezarsen) Injection: Prescribing Information","author":"US Food and Drug Administration","year":"2026"},{"key":"2026092815145986700_goag107-B109","volume-title":"Tryngolza (Olezarsen): EPAR Product Information","author":"European Medicines Agency","year":"2025"},{"key":"2026092815145986700_goag107-B110","volume-title":"Redemplo (Plozasiran) Injection: Prescribing Information","author":"US Food and Drug Administration","year":"2025"},{"key":"2026092815145986700_goag107-B111","volume-title":"Redemplo (Plozasiran): EPAR Product Information","author":"European Medicines Agency","year":"2026"},{"key":"2026092815145986700_goag107-B112","volume-title":"Waylivra (Volanesorsen): EPAR Public Assessment Report","author":"European Medicines Agency","year":"2019"},{"key":"2026092815145986700_goag107-B113","doi-asserted-by":"crossref","first-page":"1571631","DOI":"10.3389\/fmed.2025.1571631","article-title":"Risk factors associated with acute pancreatitis in diabetic ketoacidosis patients: a 11-year experience in a single tertiary medical center and comprehensive literature review","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026092815145986700_goag107-B114","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1007\/s10620-025-09246-x","article-title":"Clinical characteristics and outcomes of hypertriglyceridemic acute pancreatitis concomitant with diabetic ketoacidosis","volume":"70","author":"Liu","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026092815145986700_goag107-B115","first-page":"389","article-title":"Incidence and risk factors for diabetic ketoacidosis in hypertriglyceridemia-induced acute pancreatitis patients: a retrospective study","volume":"118","author":"Wei","year":"2026","journal-title":"Rev Esp Enferm Dig"},{"key":"2026092815145986700_goag107-B116","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1210\/clinem\/dgaf409","article-title":"Course of pregnancies and occurrence of acute pancreatitis in women with chylomicronemia","volume":"111","author":"Larouche","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092815145986700_goag107-B117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2024.10.001","article-title":"Hypertriglyceridemia-induced acute pancreatitis in pregnancy associated with CREB3L3 mutation","volume":"19","author":"Gurevitz","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026092815145986700_goag107-B118","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1513\/AnnalsATS.202407-781OC","article-title":"Propofol, triglycerides, and acute pancreatitis: a multicenter epidemiologic analysis","volume":"22","author":"Heybati","year":"2025","journal-title":"Ann Am Thorac Soc"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag107\/71446229\/goag107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag107\/71446229\/goag107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:21:38Z","timestamp":1790623298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag107\/8842575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":118,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag107","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag107"}}